Tetra Natural Health Announces the Appointment of Its Board of Directors and Chris MacLean as Chief Operating Officer

OTTAWA, Ontario, May 14, 2019 (GLOBE NEWSWIRE) -- Tetra Natural Health, a subsidiary of Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE:TBP) (OTCQB:TBPMF), is pleased to announce today that it has appointed Andre Rancourt, Greg Drohan, Guy Chamberland and Richard Giguère to its new board of directors, effective May 15, 2019.  Mr. Rancourt will assume the role of Chairman of the Board of Directors. Tetra Natural Health (TNH) also announced the appointment of Chris MacLean as Chief Operating Officer.

“I am very pleased to welcome Greg Drohan, André Rancourt and Guy Chamberland as new directors to the Tetra Natural Health Board. Their extensive experience as senior executives in the consumer products market will bring tremendous vision and skills to the execution of the strategic moves and commercial expansion of Tetra Natural Health,” says Richard Giguere, Chief Executive Officer of Tetra Natural Health. "I am also thrilled to welcome Chris MacLean as COO of Tetra Natural Health to sustain and stimulate our company’s growth."

Chris MacLean has more than ten years’ experience with small- to medium-sized start-ups. In addition to his responsibilities as COO of TNH, Chris will remain COO of Panag Pharma Inc., responsible for the company’s daily operations, securing funding and building important business relationships. In his previous roles, he helped develop Boondoc Technologies (The Rounds) and bring the company’s products to market. He played an integral part in the closing of Boondoc’s seed equity investment round, pitching the company to both angel investors and venture capital firms. Through his education and experience with new ventures, Chris has developed well-rounded knowledge in small business accounting, business development and company operations.

André Rancourt has extensive experience in the retail and professional natural health product market in Canada and the USA. For the last twenty years, he has acted as a senior executive or director in charge of marketing and driving sales of natural products across North America. His experience in negotiating contracts with distributors will be an asset, as it is a critical to the sales in this market. André Rancourt is highly experienced in management, start-ups and commercial strategies for human and agro products and acts as a consultant on many commercial strategy committees, including FIA and IRZC. He also has a considerable hands-on experience and expertise in many fields ranging from metals to the complex area of human and animal natural health products. 

Greg Drohan will be Tetra Bio-Pharma’s representative on the TNH board. While at Church and Dwight Canada, Drohan successfully merged the Church & Dwight and Carter-Horner businesses, which doubled sales revenue and helped achieve a top market share for brands such as Trojan, OxiClean, First Response, Rub A535 and Arm & Hammer. Following his successful 40-year career in the consumer products sector, Mr. Drohan set up a management consulting practice. His previous board experiences include President on the Board of Church and Dwight and director of the Ryerson University Alumni Relations Board. Drohan holds an MBA from York University and a BBM from Ryerson Polytechnical Institute.

Dr. Guy Chamberland, M.Sc., Ph.D., Master Herbalist, Chief Executive Officer and Chief Scientific Officer of Tetra Bio-Pharma, has unique expertise on the professional side of the NHP market, including the U.S. naturopathic market. His extensive and broad-based experience in both executive and scientific roles have established Dr. Chamberland as a seasoned and knowledgeable professional in the biopharmaceutical space. Dr. Chamberland has over 22 years’ experience in new drug development for the pharmaceutical industry (Canada and U.S.), with specific expertise in regulatory affairs and the development and management of clinical research protocols and clinical studies for botanical medicines. He also was a member of the investment committee of the venture capital fund Fonds Bionvation for seven years.

About Tetra Natural Health:
Tetra Natural Health inc. is a subsidiary of Tetra Bio-Pharma inc. that focuses on identification, development and marketing of hemp-based natural health products, or cannabinoids-based products authorized for sale by Health Canada. For information: www.tetranaturalhealth.com

About Tetra Bio-Pharma:
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved and FDA reviewed clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. Tetra Bio-Pharma has subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of its mission, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies. For more information visit: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company's business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company's research and development strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

For further information, please contact:
Richard Giguère
Chief Executive Officer
Tetra Natural Health
rgiguere@tetranaturalhealth.com

For investors information, please contact:
investors@tetrabiopharma.com
438-504-5784